Bristol-Myers Squibb diskutieren
Bristol-Myers Squibb
WKN: 850501 / Symbol: BMY / Name: Bristol-Myers / Aktie / Pharmazeutika / Large Cap /
41,90 €
0,64 %
Buy Bristol-Myers Squibb
Buy Bristol-Myers Squibb
Buy Bristol-Myers Squibb
Bristol-Myers Squibb (NYSE: BMY) is now covered by analysts at Daiwa Capital Markets. They set an "outperform" rating and a $70.00 price target on the stock.
Ratings data for BMY provided by MarketBeat
Bristol-Myers Squibb (NYSE: BMY) had its "underweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $59.00 price target on the stock.
Ratings data for BMY provided by MarketBeat
Bristol-Myers Squibb (NYSE: BMY) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for BMY provided by MarketBeat
Bristol-Myers Squibb (NYSE: BMY) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $84.00 price target on the stock.
Ratings data for BMY provided by MarketBeat
Bristol-Myers Squibb (NYSE: BMY) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $75.00 price target on the stock.
Ratings data for BMY provided by MarketBeat
Bristol-Myers Squibb (NYSE: BMY) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $84.00 price target on the stock.
Ratings data for BMY provided by MarketBeat
Bristol-Myers Squibb (NYSE: BMY) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $75.00 price target on the stock.
Ratings data for BMY provided by MarketBeat
Bristol-Myers Squibb (NYSE: BMY) had its price target lowered by analysts at Morgan Stanley from $57.00 to $56.00. They now have an "underweight" rating on the stock.
Ratings data for BMY provided by MarketBeat
Bristol-Myers Squibb (NYSE: BMY) had its price target lowered by analysts at Morgan Stanley from $56.00 to $50.00. They now have an "underweight" rating on the stock.
Ratings data for BMY provided by MarketBeat
Bristol-Myers Squibb (NYSE: BMY) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $81.00 to $69.00. They now have a "buy" rating on the stock.
Ratings data for BMY provided by MarketBeat
Bristol-Myers Squibb (NYSE: BMY) had its price target lowered by analysts at Bank of America Co. from $72.00 to $68.00. They now have a "buy" rating on the stock.
Ratings data for BMY provided by MarketBeat
Neueste Beiträge
Wells_Fargo___Compan in Halliburton Co. diskutieren